Warrants

Ensurge Micropower (ENMPY) announced the exercise of 19,470,726 warrants at NOK 1.00 each, subscribing for an equivalent number of new shares. The company expects NOK 19,470,726 upon payment, due October 14, 2025. The Board approved the allocation and a share capital increase, pending registration with the Norwegian Register. Post-registration, share capital will be NOK 429,142,639.50, divided into 858,285,279 shares. Unexercised warrants lapsed without compensation.

Star Navigation Systems Group Ltd. (SNAVF) closed a $475,000 private placement, issuing 47.5 million units at $0.01 each, consisting of a common share and a warrant exercisable at $0.05. Proceeds will fund working capital and development of the Star-A.D.S. system, an in-flight safety monitoring technology. While the placement introduces potential dilution, it supports Star Navigation’s growth in the aviation safety market. All securities are subject to a four-month hold period.

Soligenix, Inc. (SNGX) announced a public offering of 5,555,560 shares of common stock (or equivalents) with warrants at $1.35 per share/warrant. The warrants are immediately exercisable at $1.35, expiring in five years. Existing warrants for 1,162,064 shares will be amended to the same price and expiration. The offering, expected to close around September 29, 2025, aims to raise $7.5 million, which will fund R&D, commercialization, and general corporate needs. A.G.P./Alliance Global Partners is the sole placement agent. This offering is under an effective SEC registration statement.

Wellgistics Health (WGRX) announced a $5 million public offering of 7,142,862 shares and warrants priced at $0.70 per share. Warrants are exercisable at $0.70 immediately and expire in five years. The offering, managed by H.C. Wainwright & Co., is expected to close around September 29, 2025. Proceeds will fund working capital, operating expenses, R&D, and potential acquisitions. The offering entails significant shareholder dilution.

Orosur Mining (TSX:OMI/AIM:OMI) announced a C$20 million private placement expected to close on October 2, 2025. The offering includes up to 58,823,530 new common shares. Additionally, 260,000 common shares were issued following consultant option exercises, and 8,675,418 shares were issued from warrant exercises, raising US$701,894. Post-these issuances, Orosur will have 325,758,894 common shares in issue, with 4,701,668 options and 22,834,404 warrants outstanding.

YY Group (YYGH) closed a registered direct offering, raising $4.0 million. The offering included 9,523,812 Class A shares at $0.42 each, plus warrants for up to 14,285,718 additional shares at $0.50, exercisable within 3.5 years. FT Global Capital was the placement agent. Proceeds will fund working capital and general corporate activities. The offering was made under a shelf registration statement.

Silver One Resources (SLVRF) increased its private placement to $6,016,600 due to oversubscription, offering 21,487,857 units at $0.28 each, comprising one common share and a half-warrant. Warrants allow purchase of a share at $0.40 within three years. Proceeds will fund exploration/drilling and working capital. The offering is subject to TSX Venture Exchange approval and a four-month resale restriction. Silver One focuses on silver project development, including the Candelaria Mine in Nevada.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.

Revive Therapeutics (RVVTF) closed the first tranche of its private placement, raising $60,900 by issuing 2.9 million units at $0.021 each. It also settled $67,400 in debt by issuing 3.2 million units at the same price. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. The proceeds will fund working capital and payables. Securities are subject to a hold period expiring December 9, 2025. The offering included 100,000 compensation options to an investment dealer.

Mainz Biomed (MYNZ) has priced a $3.0 million follow-on offering at $1.35 per unit, consisting of 2,222,222 units. Each unit includes one ordinary share (or pre-funded warrant) and one Series A warrant exercisable at $1.35, expiring in five years. Maxim Group LLC is the sole placement agent. The offering is expected to close around August 5, 2025, subject to customary conditions. The offering provides minimal capital and potential shareholder dilution.